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Reversible skeletal disease and high fluoride serum levels in hematologic patients
receiving voriconazole
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We here investigate the occurrence of
fluoride intake-associated alterations in
patients with hematologic disease on tria-
zol antifungal medication. Clinical, labo-
ratory, and radiology data of overall
43 patients with hematologic malignan-
cies taking voriconazole (n  20), po-
saconazole (n  8), and itraconazole
(n  4), and a hematologic patient con-
trol group (n  11) are described. Bone
pain and radiologic evidence of periosti-
tis were exclusively observed in pa-
tients receiving long-term voriconazole.
Cessation of treatment led to clinical
improvement in all cases. In line with
clinical evidence, fluoride serum con-
centration was elevated in patients re-
ceiving voriconazole (median, 156.5 g/L;
interquartile range, 96.8 g/L; nor-
mal < 30 g/L) but not in the other treat-
ment groups (P < .001 for all compari-
sons vs voriconazole). We conclude that
serum fluoride levels were elevated on
average 5-fold above normal levels in
hematologic patients receiving voricona-
zole. Clinically relevant skeletal disease
was associated with renal insufficiency
and above 10-fold elevated fluoride lev-
els, and was reversible on termination of
voriconazole treatment. (Blood. 2012;
120(12):2390-2394)
Introduction
Invasive fungal infections are an important cause of morbidity
and mortality among patients with hematologic malignancies
undergoing intensive chemotherapy with or without autologous
or allogeneic hematopoietic stem cell transplantation.1 The
incidence of invasive aspergillosis in this patient population
ranges from 4% to 12%.2 In most patients, the diagnosis of
invasive aspergillosis triggers prolonged antifungal treatment.
Voriconazole, a fluorinated triazole compound, is an established
first-line treatment for invasive aspergillosis and is recom-
mended by most international guidelines.3,4 Its most common
side effects are well known and include visual disturbances,
hallucinations, edema, hepatotoxicity, phototoxicity, cutaneous
carcinogenesis, and drug interactions resulting from cytochrome
p450 inhibition.5 In addition, recent case reports of periostitis
and skeletal disease in solid organ recipients with long-term
voriconazole treatment have been published.6-8 It was suggested
that the fluorinated moieties of voriconazole might play a
pathogenetic role, as the radiologic picture resembled that of
“subacute fluorosis.” However, up to now, only 1 study assessed
fluoride levels in a small cohort (n  10) of primarily solid
transplant patients, including only 1 patient after bone marrow
transplantation.9 Furthermore, the effect of posaconazole, a
newer fluorinated triazole drug, on serum fluoride levels is
unknown.
We here describe fluoride levels, renal function, and musculo-
skeletal symptoms in a cohort of hematologic patients receiving
treatment with voriconazole, posaconazole, or itraconazole and
compare these with similar hematologic patients receiving no
antifungal therapy.
Methods
Patients and clinical data
We report 3 patients with bone pain under antifungal therapy with
voriconazole and an additional cohort of hematologic patients (n 43)
treated with antifungal therapy between June 2011 and August 2011 at the
Division of Hematology, University Hospital Zurich. Inclusion criteria
were a history of intensive chemotherapy and/or allogeneic stem cell
transplantation. We included all patients treated with voriconazole, itracona-
zole, and posaconazole and a control group that was treated during the same
time but did not receive antifungal treatment. Clinical information was
extracted from the patient’s charts. Bone pain was assessed by patient
interview on the day of fluoride measurement. The retrospective study was
approved by the local ethical committee of the Canton Zurich, Switzerland.
Radiologic assessment and laboratory measurements
The presence of skeletal disease was assessed by 2 independent radiologists
who were blinded for the patient’s clinical data. Radiographic signs of
periosteal reaction and skeletal disease consisted of periosteal thickening,
periosteal calcification, calcification of ligaments, and osteosclerosis.
Discordant interpretations were resolved by consensus in a second readout.
The analysis included the conventional radiographs (n 60) and CT scans
and low-dose CT scans (n  67) taken between January 2011 and August
2011. In patients with fungal infections only, radiologic studies taken after
initiation of the antifungal treatment were included.
Fluoride levels were determined from patient serum and measured by
potentiometry with an ion-selective electrode (Mettler Toledo, Seven-
Multi). Laboratory values were assessed on the date of fluoride measure-
ment, with the exception of drug serum levels, which were allowed to be
assessed during a time frame of 7 days before or after the fluoride
measurement took place. Drug levels were measured by HPLC mass
spectrometry (Finnigan TSQ LC/MS) at baseline.
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The glomerular filtration rate was calculated according the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Definition of medication-induced skeletal disease
Diagnosis of medication-induced skeletal disease required (1) typical
clinical findings, such as a subacute disseminated musculoskeletal pain
syndrome; (2) radiographic findings, such as periosteal appositions or
disseminated focal tracer uptake in a bone scintigraphy; (3) absence of an
alternative diagnosis, such as relapse, secondary cancer, and arthritis; and
(4) prompt improvement after drug cessation.
Statistical analysis
Data were reported as proportions, means with SDs, or medians with
interquartile ranges (IQRs). Fluoride levels were compared by the Kruskal-
Wallis test. All reported P values are 2-sided, and P  .05 was considered to
be significant. The Spearman rank correlation coefficient was used to




We report 3 patients on long-term voriconazole treatment who
developed clinically significant skeletal disease, which was com-
pletely reversible after termination of voriconazole (Table 1). All
3 patients were female allogeneic stem cell transplant recipients
with cyclosporine-related moderate chronic renal failure. Dissemi-
nated bone pain started between 3 and 7.5 months of voriconazole
treatment. Laboratory findings included an elevated alkaline phos-
phatase and bone-specific alkaline phosphatase, normal levels of
calcium, phosphate, parathyroid hormone, 25-hydroxyvitamin D,
and a slightly elevated urinary deoxypyridinoline/creatinine quo-
tient. Conventional radiographs, CT scans, and bone scintigraphy
revealed periosteal appositions and focal tracer uptake, respec-
tively (Figures 1 and 2). CT scans of the chest and abdomen
showed no signs of secondary malignancies, and bone marrow
biopsies ruled out recurrence of the acute leukemia. Patients 1 and
2 were initially misdiagnosed as having an unusual musculoskel-
etal presentation of GVHD; hence, the immunosuppression was
intensified. However, the pain was only temporarily attenuated by
corticosteroids and methotrexate but disappeared almost com-
pletely in all 3 patients within 4 days of voriconazole cessation. The
diagnosis of voriconazole-induced skeletal disease was made only
retrospectively in patient 1, 20 months after occurrence of the first
symptoms in patient 2, and without delay in patient 3. Serum
fluoride measurements at diagnosis were available for patients
2 and 3 with 10-fold elevated levels and a marked decrease
within 3 weeks of voriconazole cessation (81% and 57% of precessation
values, respectively). Long-term follow up of 5.5 years after the initial
diagnosis revealed complete resolution of the skeletal changes in
patient 1 (Figure 1).
Results of the cohort with hematologic malignancies receiving
antifungal therapy and the control group
The main patient characteristics of overall 32 patients with
hematologic malignancies taking voriconazole (n 20), posacona-
zole (n 8), and itraconazole (n 4), as well as a hematologic
patient control group (n 11) not receiving antifungal therapy are
shown in Table 2 and in more detail in Supplemental Tables 1 and
2 (available on the Blood Web site; see the Supplemental Materials
link at the top of the online article). The 3 patients with proven
voriconazole-induced skeletal disease were not included in this
analysis. Serum fluoride levels were significantly elevated in
patients receiving voriconazole (median, 157 g/L; IQR, 97 g/L)
compared with itraconazole (median, 30 g/L; IQR, 28 g/L),
posaconazole (median, 30 g/L; IQR, 0 g/L), and the control
group without antifungal medication (median, 30 g/L; IQR,
28 g/L; P  .001 for all comparisons; Figure 3). The fluoride
level in the voriconazole treatment group was inversely correlated
Table 1. Clinical and laboratory characteristics of patients with voriconazole-induced skeletal disease
Patient 1 Patient 2 Patient 3
Diagnosis AML AML ALL
Age at diagnosis, y 46 37 55
Sex Female Female Female
Body mass index, kg/m2 17.5 24.4 19.4
Allogeneic stem cell transplantation
Conditioning Cy/TBI Cy/TBI Cy/TBI
Donor MSD MSD MSD
GVHD prophylaxis CsA/MTX CsA/MTX CsA/MTX
Voriconazole treatment days until onset of skeletal disease 100 177 226
Total voriconazole dose until onset of skeletal disease, g 55 97.4 133.6
Median voriconazole level (IQR)*/no. of measurements 1.6 (0.85)/12 1.95 (0.9)/14 1.2 (1.35)/15
Laboratory values during voriconazole treatment/3 wks after
voriconazole cessation
Glomerular filtration rate, mL/min† 57/65 31/50 32/46
ALP, U/L‡ 195/102 384/214 202/125
ALT, U/L§ 106/92 38/30 9/13
Fluoride level, g/L NA 363/70 316/136
CsA level, g/L 154/NA 106/50 226/179
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Cy/TBI, cyclophosphamide/total body irradiation (12 Gy); MSD, HLA-matched sibling donor;
CsA/MTX, cyclosporine/methotrexate; ALP, alkaline phosphatase; ALT, alanine aminotransferase; and NA, not applicable.
*Target serum levels for voriconazole 1.0-6.0 mg/L, posaconazole  1.0 mg/L, and itraconazole  1.0 mg/L.
†According to the CKD-EPI formula.
‡Normal: 35-104 U/L.
§Normal: 10-35 U/L.
Normal:  30 g/L.
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to the glomerular filtration rate (Spearman rank correlation coeffi-
cient 0.74; P  .001; Figure 4). Radiologically typical skel-
etal disease (periosteal appositions, abnormal calcifications)
was seen in the CT scan of 1 asymptomatic patient (5%) in the
voriconazole group and none in the other treatment groups.
Disseminated bone pain consistent with skeletal disease was
present in 3 (15%) patients in the voriconazole group and none in
the other treatment groups. No signs of skeletal disease were
detected in 2 of these patients by chest CT scan, whereas the third
patient had no radiologic examinations performed during the
observation phase. Additional fluorinated drugs were given in only
1 patient (posaconazole group), and no increase in serum fluoride
level was noted.
Discussion
To the best of our knowledge, this is the first study to systematically
analyze the impact of voriconazole on fluoride levels and skeletal
disease in hematologic patients. Fluoride levels are elevated in all
patients taking voriconazole irrespective of treatment duration.
However, severe periostitis and skeletal disease are relatively rare
and most probably result from prolonged therapy, impaired renal
function, and consecutively persistent high fluoride serum levels.
The clinical presentation and the radiologic findings of the
affected patients are impressive and can lead to considerable
confusion as, for example, in our institution where the first
affected patients have been mistakenly treated for chronic musculo-
skeletal GVHD.
Voriconazole-induced skeletal disease shares many features of
skeletal fluorosis, a condition that has been known for decades.10-12
In Western countries, fluoride poisoning is rare but has been linked
to occupational exposure, ingestion of tainted wine, excessive
inhalation of fluorinated anesthetics, and iatrogenic because of the
prescription of fluoride supplements.13-16 The World Health Organi-
zation states that a daily fluoride intake of 6 mg bears a risk of
skeletal events.17
Voriconazole contains 3 fluoride atoms, which account for
16.3% of the total molecular weight of the compound. It has an oral
bioavailability of 96%. Thus, in theory, the calculated daily fluoride
intake at a standard dose may be as high as 62.6 mg and therefore
exceeds 10-fold the fluoride toxicity threshold defined by the World
Health Organization.
But why do only some patients on voriconazole treatment
develop clinically relevant skeletal disease? (1) Fluoride is mainly
Figure 1. Radiographic findings and bone scintigraphy in patient 1. (A) Techne-
tium 99m-methyl-diphosphonate bone scintigraphy showing marked tracer uptake in
the entire skeleton, most pronounced in the spine and pelvis (left). There are multiple
active spots in bones of both hands (right). (B) Plain film showing marked periosteal
bone apposition on diaphysis of the phalanges of the left hand (arrows). Findings are
typical for hypertrophic osteoarthropathy. The image was taken after 9 months of
voriconazole therapy. (C) Plain film showing resolution of periosteal bone appositions
on diaphysis of the phalanges (arrows). The image was taken 5 years after cessation
of voriconazole therapy.
Figure 2. Radiographic findings and bone scintigra-
phy in patient 2. (A) Plain film showing marked perios-
teal bone apposition on radial and distal diaphysis of the
first metacarpal bone of the right hand (arrow).
(B) Technetium 99m-methyl-diphosphonate bone scintig-
raphy showing marked tracer uptake in the entire skel-
eton, most pronounced in the spine and pelvis. There are
active spots in bones of both hands and feet. (C) CT scan
of the entire skeleton revealed bone appositions in
various sites of the skeleton (arrows): at the caudal
margin of the glenoid (top), at the dorsal ribs (middle),
and periacetabular on both sides (bottom). Findings are
typical of hypertrophic osteoarthropathy.
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excreted by the kidneys, and an impaired renal function leads to
higher circulating fluoride levels.18,19 Indeed, the fluoride level in
our voriconazole treatment group was inversely correlated to the
glomerular filtration rate, and all our patients with proven
voriconazole-induced skeletal disease had moderate to severe
chronic renal failure. However, chronic renal failure alone does not
necessarily translate into skeletal disease as, for example, 6 addi-
tional patients with voriconazole treatment and moderate chronic
renal failure did not show evidence of toxicity. (2) It is known from
endemic fluorosis that prolonged intake promotes toxicity, and it
seems reasonable to assume that this also holds true for patients
exposed to fluorinated drugs, even though our data lack the
statistical power to test this. (3) We hypothesize that pharmacoge-
netics and drug-drug interactions may account in part for the
interindividual differences. (4) We speculate that inflammatory
processes play an additional role as the symptoms in our patients
were temporarily attenuated by adding corticosteroids and metho-
trexate and the pain rapidly resolved after cessation of voricona-
zole, even though the radiographically visible skeletal changes
clearly needed more time to resolve.
Posaconazole, another triazole drug containing fluorinated
moieties, did not cause fluoride excess in our patient cohort.
However, the number of patients receiving posaconazole was
rather small, the treatment duration short, and the median serum
level low. Nevertheless, in 2 patients on long-term posaconazole
treatment ( 20 days) and chronic renal failure (glomerular
filtration rate 90 mL/min), no fluoride excess was observed.
There are limitations of our study. First, it is a retrospective
single-center study, which lacks the power to draw firm conclu-
sions regarding the prevalence of the disorder and its observational,
descriptive character does not allow statements about the precise
mechanism of disease. Second, because of the retrospective nature
of the radiologic assessment, no systematic radiographic screening
Table 2. Clinical and laboratory characteristics of patients with hematologic malignancies taking voriconazole, posaconazole, and
itraconazole, and a hematologic patient control group not receiving antifungal therapy
Voriconazole (n  20) Posaconazole (n  8) Itraconazole (n  4) Control group (n  11)
Mean age, y 55.1 54.9 49.5 56.6
Male sex, % 10 (50) 3 (37.5) 3 (75) 7 (63.6)
Stem cell transplantation, % 15 (75) 3 (37.5) 4 (100) 10 (90.9)
Median antifungal treatment, days (IQR) 98 (220) 13 (576) 587 (1400) NA
Median drug serum concentration (IQR)* 1.7 (1.8) 0.24 (1.17) 1.95 (1.75) NA
Median glomerular filtration rate (IQR)† 77.5 (43.6) 92.2(33.8) 70.8 (45.7) 74.2 (18.9)
Cyclosporine treatment, % 9 (45) 2 (25) 0 6 (54.5)
Median cyclosporine blood concentration, g/L (IQR) 92 (102.5) 53.5 NA 104 (141.5)
Median ALP‡ (IQR) 111 (76.5) 66 (103) 120 (138) 71 (31)
Median ALT§ (IQR) 30 (12.5) 36 (30) 70.5 (90) 20 (18)
Median fluoride level (IQR) 156.5 (96.8)  30 (0)  30 (28)  30 (32)
Median no. of radiographic studies (IQR) 2 (3.5) 0.5 (1) 1 (0.25) 3 (3.5)
Median no. of CT scans (IQR) 1 (1) 0.5 (1) 1 (0.25) 2 (2)
Radiographic evidence of periostitis, % 1 (5) 0 0 0
Bone pain, % 3 (15) 0 0 0
NA indicates not applicable; ALP, alkaline phosphatase; and ALT, alanine aminotransferase.
*Target serum levels for voriconazole 1.0-6.0 mg/L, posaconazole  1.0 mg/L, and itraconazole  1.0 mg/L.
†According to the CKD-EPI formula.
‡Normal: 35-104 U/L.
§Normal: 10-35 U/L.
Normal:  30 g/L.
Figure 3. Serum fluoride levels. The boxplots represent median, IQR, and the
whiskers, 95% confidence intervals. Serum fluoride levels were significantly elevated
in patients receiving voriconazole (median, 157 g/L; IQR, 97 g/L) compared with
itraconazole (median  30 g/L; IQR, 28 g/L), posaconazole (median  30 g/L,
IQR, 0 g/L), and the control group without antifungal medication (median  30 g/L;
IQR, 28 g/L). P  .001 for all comparisons.
Figure 4. Correlation between the glomerular filtration rate, as calculated by the
CKD-EPI formula, and the serum fluoride levels for the patients taking
voriconazole. Spearman rank correlation coefficient  0.74; P  .001.
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was available. This might have led to a bias regarding the detection
rate of skeletal disease. Third, more data for long-term posacona-
zole treatment must be obtained to draw definite conclusions on
fluoride levels and possible associated clinical implications for
patients receiving this drug.
So far, no treatment of voriconazole-induced periostitis or
chronic fluoride intoxication has been established, except with-
drawal of the causing agent. Whereas antifungal treatment was stopped
permanently in 2 of our patients, the third was put on itraconazole,
another triazole drug yet containing chlorinated, but not fluorinated,
moieties (Figure 5). Bone pain resolved rapidly in all patients.
In conclusion, voriconazole-induced periostitis and skeletal
disease can occur in hematologic patients; and even though
causality cannot yet be fully proven, fluoride is likely to contribute
to the clinical picture. Physicians caring for patients on long-term
voriconazole should be aware of this side effect, as it severely
affects the quality of life and, when misdiagnosed, may lead to
inappropriate therapy. In our experience, bone scintigraphy is a
useful test when a voriconazole-induced periostitis is suspected,
but other causes of skeletal disease still have to be ruled out. On
discontinuation of voriconazole, skeletal disease seems to be fully
reversible over time.
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Figure 5. Chemical structures. (A) Posaconazole. (B) Itraconazole. (C) Voriconazole.
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